Lido Advisors LLC Has $12.04 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Lido Advisors LLC raised its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 10.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,747 shares of the medical equipment provider's stock after purchasing an additional 13,018 shares during the period. Lido Advisors LLC's holdings in Boston Scientific were worth $12,036,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Northern Trust Corp boosted its holdings in shares of Boston Scientific by 18.0% in the fourth quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock valued at $1,303,681,000 after buying an additional 2,221,790 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Boston Scientific by 4.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 1,170,149 shares of the medical equipment provider's stock valued at $104,518,000 after buying an additional 49,683 shares during the period. Optiver Holding B.V. acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $187,000. Berger Financial Group Inc boosted its holdings in shares of Boston Scientific by 23.3% in the fourth quarter. Berger Financial Group Inc now owns 10,178 shares of the medical equipment provider's stock valued at $909,000 after buying an additional 1,922 shares during the period. Finally, Gerber Kawasaki Wealth & Investment Management acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $222,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.29 during midday trading on Thursday, reaching $103.16. 8,205,533 shares of the company's stock were exchanged, compared to its average volume of 6,347,818. Boston Scientific Co. has a 52 week low of $70.97 and a 52 week high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market cap of $152.59 billion, a price-to-earnings ratio of 82.53, a P/E/G ratio of 2.79 and a beta of 0.73. The stock's 50-day simple moving average is $98.53 and its 200 day simple moving average is $95.13.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter last year, the company posted $0.56 earnings per share. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. On average, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Robert W. Baird upped their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Evercore ISI upped their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Needham & Company LLC upped their price target on shares of Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Morgan Stanley lifted their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Finally, Piper Sandler increased their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Twenty-three investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $114.52.

Insider Transactions at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. The trade was a 11.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,009 shares of company stock worth $14,407,381 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.